Defining the Molecular Biology of Inflammatory Breast Cancer

Seminars in Oncology

Volumn 35, Issue 1, 2008, Pages 41-50

  Charafe Jauffret, Emmanuelle ^a,b   Tarpin, Carole ^a   Viens, Patrice ^a,b   Bertucci, François ^a,b  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVEXIN; ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE IX; CATENIN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; LAPATINIB; MOLECULAR MARKER; PROTEIN P53; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UVOMORULIN;

ADJUVANT THERAPY; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE THERAPY; HUMAN; INFLAMMATORY BREAST CANCER; LYMPHANGIOGENESIS; METASTASIS; MOLECULAR BIOLOGY; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; CADHERINS; CATENINS; CHEMOKINES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; INFLAMMATION; MOLECULAR BIOLOGY; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CHEMOKINE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 39549121254     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.11.015     Document Type: Article

References (92)

1. Chang S., Parker S.L., Pham T., et al. Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program of the National Cancer Institute, 1975-1992. Cancer 82 (1998) 2366-2372
2. Gonzalez-Angulo A.M., Hortobagyi G.N., and Esteva F.J. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11 (2006) 857-867
3. Jaiyesimi I.A., Buzdar A.U., and Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 10 (1992) 1014-1024
4. Kerlikowske K., Miglioretti D.L., Buist D.S., et al. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 99 (2007) 1335-1339
5. Ravdin P.M., Cronin K.A., Howlader N., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 (2007) 1670-1674
6. Hance K.W., Anderson W.F., Devesa S.S., et al. Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program at the National Cancer Institute. J Natl Cancer Inst 97 (2005) 966-975
7. Ueno N.T., Buzdar A.U., Singletary S.E., et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol 40 (1997) 321-329
8. Chevallier B., Asselain B., Kunlin A., et al. Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis. Cancer 60 (1987) 897-902
9. Cristofanilli M., Buzdar A.U., Sneige N., et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 92 (2001) 1775-1782
10. Feldman L.D., Hortobagyi G.N., Buzdar A.U., et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46 (1986) 2578-2581
11. Palangie T., Mosseri V., Mihura J., et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 30A (1994) 921-927
12. Sataloff D.M., Mason B.A., Prestipino A.J., et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180 (1995) 297-306
13. Cristofanilli M., Gonzalez-Angulo A.M., Buzdar A.U., et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M.D. Anderson Cancer Center experience. Clin Breast Cancer 4 (2004) 415-419
14. Vincent-Salomon A., Carton M., Freneaux P., et al. ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy. Eur J Cancer 36 (2000) 586-591
15. Cristofanilli M., Buzdar A.U., and Hortobagyi G.N. Update on the management of inflammatory breast cancer. Oncologist 8 (2003) 141-148
16. Kleer C.G., van Golen K.L., and Merajver S.D. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2 (2000) 423-429
17. Paradiso A., Tommasi S., Brandi M., et al. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer 64 (1989) 1922-1927
18. Charafe-Jauffret E., Tarpin C., Bardou V.J., et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol 202 (2004) 265-273
19. Van den Eynden G.G., Van der Auwera I., Van Laere S., et al. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat 85 (2004) 13-22
20. Somlo G., Frankel P., Chow W., et al. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol 22 (2004) 1839-1848
21. Guerin M., Gabillot M., Mathieu M.C., et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer 43 (1989) 201-208
22. Lerebours F., Bertheau P., Bieche I., et al. Evidence of chromosome regions and gene involvement in inflammatory breast cancer. Int J Cancer 102 (2002) 618-622
23. Charpin C., Bonnier P., Khouzami A., et al. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Anticancer Res 12 (1992) 591-597
24. Sawaki M., Ito Y., Akiyama F., et al. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer. Breast Cancer 13 (2006) 172-178
25. Charafe-Jauffret E., Mrad K., Intidhar L.S., et al. Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. Breast 16 (2007) 352-358
26. Parton M., Dowsett M., Ashley S., et al. High incidence of HER-2 positivity in inflammatory breast cancer. Breast 13 (2004) 97-103
27. Prost S., Le M.G., Douc-Rasy S., et al. Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer 58 (1994) 763-768
28. Van Pelt A.E., Mohsin S., Elledge R.M., et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin. Breast Cancer 4 (2003) 348-353
29. Nieto Y., Nawaz S., Shpall E.J., et al. Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy. Clin Cancer Res 10 (2004) 2609-2617
30. Hurley J., Doliny P., Reis I., et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24 (2006) 1831-1838
31. Limentani S.A., Brufsky A.M., Erban J.K., et al. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 25 (2007) 1232-1238
32. Dawood S., Gonzalez-Angulo A.M., Peintinger F., et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M.D. Anderson experience. Cancer 110 (2007) 1195-1200
33. Le M.G., Arriagada R., Bahi J., et al. Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer?. Breast 15 (2006) 355-362
34. Nieto Y., Nawaz F., Jones R.B., et al. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol 25 (2007) 4405-4413
35. Dawood S., and Cristofanilli M. What progress have we made in managing inflammatory breast cancer?. Oncology (Williston Park) 21 (2007) 673-679
36. Nigro J.M., Baker S.J., Preisinger A.C., et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342 (1989) 705-708
37. Davidoff A.M., Humphrey P.A., Iglehart J.D., et al. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A 88 (1991) 5006-5010
38. Faille A., De Cremoux P., Extra J.M., et al. p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer 69 (1994) 1145-1150
39. Moll U.M., Riou G., and Levine A.J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A 89 (1992) 7262-7266
40. Riou G., Le M.G., Travagli J.P., et al. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst 85 (1993) 1765-1767
41. Resetkova E., Gonzalez-Angulo A.M., Sneige N., et al. Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. Cancer 101 (2004) 913-917
42. Yang C.H., and Cristofanilli M. The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer. Future Oncol 2 (2006) 247-255
43. McCarthy N.J., Yang X., Linnoila I.R., et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 8 (2002) 3857-3862
44. Colpaert C.G., Vermeulen P.B., Fox S.B., et al. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat 81 (2003) 137-147
45. Van der Auwera I., Van Laere S.J., Van den Eynden G.G., et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 10 (2004) 7965-7971
46. Shirakawa K., Furuhata S., Watanabe I., et al. Induction of vasculogenesis in breast cancer models. Br J Cancer 87 (2002) 1454-1461
47. Wedam S.B., Low J.A., Yang S.X., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24 (2006) 769-777
48. Kleer C.G., van Golen K.L., Braun T., et al. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol 14 (2001) 458-464
49. Oka H., Shiozaki H., Kobayashi K., et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 53 (1993) 1696-1701
50. Hoffmeyer M.R., Wall K.M., and Dharmawardhane S.F. In vitro analysis of the invasive phenotype of SUM 149, an inflammatory breast cancer cell line. Cancer Cell Int 5 (2005) 11
51. Tomlinson J.S., Alpaugh M.L., and Barsky S.H. An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res 61 (2001) 5231-5241
52. Alpaugh M.L., Tomlinson J.S., Kasraeian S., et al. Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene 21 (2002) 3631-3643
53. Alpaugh M.L., Tomlinson J.S., Ye Y., et al. Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol 161 (2002) 619-628
54. Cabioglu N., Gong Y., Islam R., et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol 18 (2007) 1021-1029
55. Andre F., Cabioglu N., Assi H., et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 17 (2006) 945-951
56. Cabioglu N., Sahin A., Doucet M., et al. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metast 22 (2005) 39-46
57. Minn A.J., Gupta G.P., Padua D., et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A 104 (2007) 6740-6745
58. Smith M.C., Luker K.E., Garbow J.R., et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64 (2004) 8604-8612
59. Forozan F., Veldman R., Ammerman C.A., et al. Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer 81 (1999) 1328-1334
60. Alpaugh M.L., Tomlinson J.S., Shao Z.M., et al. A novel human xenograft model of inflammatory breast cancer. Cancer Res 59 (1999) 5079-5084
61. Shirakawa K., Tsuda H., Heike Y., et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 61 (2001) 445-451
62. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
63. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98 (2001) 10869-10874
64. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100 (2003) 8418-8423
65. Shirakawa K., Kobayashi H., Sobajima J., et al. Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res 5 (2003) 136-139
66. Maniotis A.J., Folberg R., Hess A., et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155 (1999) 739-752
67. van Golen K.L., Davies S., Wu Z.F., et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 5 (1999) 2511-2519
68. Sahai E., and Marshall C.J. RHO-GTPases and cancer. Nat Rev Cancer 2 (2002) 133-142
69. van Golen K.L., Wu Z.F., Qiao X.T., et al. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 60 (2000) 5832-5838
70. van Golen K.L., Wu Z.F., Qiao X.T., et al. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2 (2000) 418-425
71. Wu M., Wu Z.F., Kumar-Sinha C., et al. RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. Breast Cancer Res Treat 84 (2004) 3-12
72. van Golen K.L., Bao L.W., Pan Q., et al. Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin Exp Metast 19 (2002) 301-311
73. Kleer C.G., van Golen K.L., Zhang Y., et al. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 160 (2002) 579-584
74. Kleer C.G., Griffith K.A., Sabel M.S., et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat 93 (2005) 101-110
75. van Golen K.L., Bao L., DiVito M.M., et al. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther 1 (2002) 575-583
76. Kleer C.G., Zhang Y., Pan Q., et al. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 21 (2002) 3172-3180
77. Kleer C.G., Zhang Y., Pan Q., et al. WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer. Neoplasia 6 (2004) 179-185
78. Kleer C.G., Zhang Y., Pan Q., et al. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 6 (2004) R110-R115
79. Bertucci F., Finetti P., Rougemont J., et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 64 (2004) 8558-8565
80. Bertucci F., Finetti P., Rougemont J., et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 65 (2005) 2170-2178
81. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005) 5678-5685
82. Garcia S., Dales J.P., Jacquemier J., et al. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. Br J Cancer 96 (2007) 329-335
83. Van Laere S., Van der Auwera I., Van den Eynden G.G., et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat 93 (2005) 237-246
84. Van Laere S.J., Van der Auwera I., Van den Eynden G.G., et al. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res 12 (2006) 3249-3256
85. Van Laere S., Van der Auwera I., Van den Eynden G., et al. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br J Cancer 97 (2007) 659-669
86. Van Laere S., Van der Auwera I., Van den Eynden G., et al. Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis. Br J Cancer 97 (2007) 165-174
87. Van den Eynden G.G., Van Laere S.J., Van der Auwera I., et al. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat 95 (2006) 219-228
88. Bieche I., Lerebours F., Tozlu S., et al. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 10 (2004) 6789-6795
89. Dressman H.K., Hans C., Bild A., et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 12 (2006) 819-826
90. Nguyen D.M., Sam K., Tsimelzon A., et al. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res 12 (2006) 5047-5054
91. Lee B., and Tannenbaum N. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the Breast Clinic of Memorial Hospital. Surg Gynecol Obstet 39 (1924) 580-595
92. Stingl J., and Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7 (2007) 791-799